PECAM1 and neoplasm: Compared with non-responders, patients with a partial response showed a significantly lower risk of relapse when their residual tumor exhibited high FOXP3, CD68, CD83, CD31 and CD34 content and IL15 expression but a low CD138 concentration (Figure 2B).